Medicxi announced the close of its €500 million Medicxi V vehicle, reinforcing the firm’s position as a major European life sciences investor and adding significant capital to expand its long-standing asset-centric company creation strategy.
The fund, which exceeded its target, attracted strong participation from returning limited partners along with a curated group of new institutional investors. With this latest close, Medicxi strengthens its ability to build and invest in biotechnology companies with clearly defined product visions focused on meaningful patient impact.
The firm has delivered notable results since its previous raise. Its portfolio has generated more than $1 billion in realized value, supported by clinical progress from companies such as Vaxcyte, Merus, and Abivax, as well as several high-profile acquisitions involving ViceBio by Sanofi, Versant Biosciences by Eli Lilly, and Profound Biosciences by Genmab. Alongside these outcomes, Medicxi has formed 16 new companies and achieved over 20 positive clinical data readouts, reinforcing the advancement of its asset-centric approach.
With Fund V, Medicxi plans to continue backing drug hunters, founders, and scientific leaders building focused biotechnology companies targeting specific therapeutic assets. The fund will also make follow-on investments in existing portfolio businesses across various stages of development, provided they align with the firm’s product-driven value creation philosophy.
The firm also announced a vital leadership update with the promotion of Shyam Masrani to Partner. Masrani has played a central role in the firm’s investments in Merus and ProfoundBio and currently holds board seats at Acera Therapeutics, T-CypherBio, and Petalion Therapeutics. Fund V will be managed by investing partners Francesco De Rubertis, Giovanni Mariggi, Nick Williams, and Masrani.
Medicxi continues to leverage more than two decades of drug development and company-building expertise, supporting therapeutics with the potential to address unmet medical needs. Additional information about the firm and its portfolio can be found at its website.
KEY QUOTES:
“Medicxi’s longstanding success has been founded on its unique ties to leading global pharmaceutical companies and its world-class team of drug hunters and clinicians. The new €500 million fund will enable Medicxi to provide the critical capital, expertise and experience to deliver transformative therapies for patients.”
Francesco De Rubertis, Co-founder and Partner at Medicxi
“Medicxi’s differentiated, capital-efficient investment strategy is rapidly scaling and we have now raised six funds in the last 10 years, totalling over €2.0 billion. We are extremely grateful for the support that we have received from our existing and new limited partners, and we are excited to continue investing in cutting-edge science and accelerating the discovery of life-changing medicines for patients.”
Giovanni Mariggi, Co-founder and Partner at Medicxi
